Axsome Therapeutics Revenue vs. Number Of Shares Shorted
| AXSM Stock | USD 98.19 3.59 3.79% |
Total Revenue | First Reported 2013-12-31 | Previous Quarter 87.2 M | Current Value 104.8 M | Quarterly Volatility 30.1 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.72 | 0.9037 |
|
|
For Axsome Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Axsome Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Axsome Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Axsome Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Axsome Therapeutics over time as well as its relative position and ranking within its peers.
Axsome |
Axsome Therapeutics' Revenue Breakdown by Earning Segment
Check out Trending Equities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.58) | Revenue Per Share 7.108 | Quarterly Revenue Growth 0.813 | Return On Assets (0.26) | Return On Equity (1.72) |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Axsome Therapeutics Number Of Shares Shorted vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Axsome Therapeutics's current stock value. Our valuation model uses many indicators to compare Axsome Therapeutics value to that of its competitors to determine the firm's financial worth. Axsome Therapeutics is rated below average in revenue category among its peers. It is rated below average in number of shares shorted category among its peers making about 0.03 of Number Of Shares Shorted per Revenue. The ratio of Revenue to Number Of Shares Shorted for Axsome Therapeutics is roughly 35.71 . At this time, Axsome Therapeutics' Total Revenue is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Axsome Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Axsome Revenue vs. Competition
Axsome Therapeutics is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 7.5 Billion. Axsome Therapeutics holds roughly 270.6 Million in revenue claiming about 4% of equities under Health Care industry.
Axsome Number Of Shares Shorted vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Axsome Therapeutics |
| = | 270.6 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Axsome Therapeutics |
| = | 7.58 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Axsome Number Of Shares Shorted Comparison
Axsome Therapeutics is currently under evaluation in number of shares shorted category among its peers.
Axsome Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Axsome Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Axsome Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Axsome Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Axsome Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -231.8 M | -220.2 M | |
| Income Before Tax | -238.3 M | -226.4 M | |
| Total Other Income Expense Net | -6.5 M | -6.1 M | |
| Net Loss | -239.2 M | -227.3 M | |
| Income Tax Expense | 960 K | 912 K | |
| Net Loss | -239.2 M | -227.3 M | |
| Net Loss | -168.4 M | -160 M | |
| Interest Income | 1.4 M | 1.2 M | |
| Net Interest Income | -6.5 M | -6.1 M | |
| Non Operating Income Net Other | -5.1 M | -4.9 M | |
| Change To Netincome | 45.9 M | 48.2 M | |
| Net Loss | (5.27) | (5.00) | |
| Income Quality | 0.61 | 0.84 | |
| Net Income Per E B T | 1.00 | 0.82 |
Axsome Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Axsome Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Axsome Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Axsome Therapeutics' important profitability drivers and their relationship over time.
Use Axsome Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Axsome Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Axsome Therapeutics will appreciate offsetting losses from the drop in the long position's value.Axsome Therapeutics Pair Trading
Axsome Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Axsome Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Axsome Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Axsome Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Axsome Therapeutics to buy it.
The correlation of Axsome Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Axsome Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Axsome Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Axsome Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Axsome Therapeutics position
In addition to having Axsome Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sport Products Thematic Idea Now
Sport Products
Companies manufacturing sporting goods and accessories. The Sport Products theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sport Products Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
To fully project Axsome Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Axsome Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Axsome Therapeutics' income statement, its balance sheet, and the statement of cash flows.